Erratum: Mephedrone pharmacokinetics after intravenous and oral administration in rats: Relation to pharmacodynamics (Psychopharmacology 229 (295-306) DOI:10.1007/s00213-013-3108-7);Mephedrone pharmacokinetics after intravenous and oral administration in rats: Relation to pharmacodynamics

Psychopharmacology

Volumn 229, Issue 2, 2013, Pages 295-306

  Martinez Clemente J ^a   Lopez Arnau R ^a   Carbo M ^b,c   Pubill, D ^a   Camarasa, J ^a   Escubedo, E ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Locomotor activity; Mephedrone; Pharmacokinetics; PK PD modeling; Rat

Indexed keywords

4' METHYLMETHCATHINONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; FIRST PASS EFFECT; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MASS SPECTROMETRY; METABOLITE; NONHUMAN; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; RAT; STRUCTURE ANALYSIS; SUBSTANCE ABUSE;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METABOLIC NETWORKS AND PATHWAYS; METHAMPHETAMINE; MOTOR ACTIVITY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84883446798     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3283-6     Document Type: Erratum

References (30)

1. Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, Foster DM (1998) SAAM II: Simulation, Analysis and Modeling Software for tracer and pharmacokinetics studies. Metabolism 147:484-492
2. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192-1203
3. Baumann MH, Partilla JS, Lehner KR (2013) Psychoactive "bath salts": not so soothing. Eur J Pharmacol 698:1-5
4. Brunt TM, Koeter MW, Niesink RJ, van den Brink W (2012) Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology (Berl) 220:751-762
5. Chu T, Kumagai Y, DiStefano EW, Cho AK (1996) Disposition of mehylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51:789-796
6. Cozzi NV, Sievert MK, Shulgin AT, Jacobill P, Rhuolo AE (1999) Inhibition of plasma membrane monoamine transporters by betaketoamphetamines. Eur J Pharmacol 381:63-69
7. Csajka C, Verotta D (2006) Pharmacokinetic-pharmacodynamic modeling: history and perspectives. J Pharmacokinet Pharmacodyn 33:227-279
8. Dickson AJ, Vorce SP, Levine B, Past MR (2010) Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol 34:162-168
9. Fonsart J, Menet MC, Debray M, Hirt D, Noble F, Scherrmann JM, Declèves X (2009) Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA). Toxicol Appl Pharmacol 241:339-347
10. Food and Drug Administration Center for Drug Evaluation and Research (2005) Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov/cder/guidance/index.htm. Accessed October 14, 2012
11. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339:530-536
12. Hitchcock SA, Pennington LD (2006) Structure-brain exposure relationships. J Med Chem 49:7559-7583
13. 2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther 340:286-289
14. Khreit OI, Grant MH, Zhang T, Henderson C, Watson DG, Sutcliffe OB (2013) Elucidation of the phase I and phase II metabolic pathways of (±)-4′-methylmethcathinone (4-MMC) and (±)-4′- (trifluoromethyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MS(2). J Pharm Biomed Anal 72:177-185
15. López-Arnau R, Martínez-Clemente J, Pubill D, Escubedo E, Camarasa J (2012) Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol 167:407-420
16. Martínez-Clemente J, Escubedo E, Pubill D, Camarasa J (2012) Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22:231-236
17. Maskell PD, De Paoli G, Seneviratne C, Pounde DJ (2011) Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 35:188-191
18. Meyer MR, Wilhelm J, Peters FT, Maurer HH (2010) Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 397:1225-1233
19. Nagai F, Nonaka R, Satoh K, Kamimura SHK (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132-137
20. Porchet HC, Benowitz NL, Sheiner LB, Copelan JR (1987) Apparent tolerance to the acute effect of nicotine results in part from distribution kinetics. J Clin Invest 80:466-741
21. Schechter MD (1990) Rats become acutely tolerant to cathine after amphetamine or cathinone administration. Psychopharmacology (Berl) 101:126-131
22. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, Davey Z, Corkery J, Siemann H, Scherbaum N, Farre M, Torrens M, Demetrovics Z, Ghodse AH (2011) Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 214:593-602
23. Sheiner LB, Stanki DR, Vozeh S, Miller RD, Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-370
24. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458-470
25. Sørensen LK (2011) Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatography-electrospray tandem mass spectrometry. J Chromatogr B 879:727-736
26. Varner KJ, Daigle K, Weed PF, Lewis PB, Mahne SE, Sankaranarayanan A, Winsauer PJ (2013) Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats. Psychopharmacology (Berl) 225:675-685
27. Wilkinson P, Van Dyke C, Jatlow P, Barash P, Byck (1980) Intranasal and oral cocaine kinetics. Clin Pharmacol Ther 27:386-394
28. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J (2011) Mephedrone: use, subjective effects and health risks. Addiction 106:1991-1996
29. Wood DM, Davies S, Greene SL, Button J, Holt DW, Ramsey J, Dargan PI (2010a) Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 48:924-927
30. Wood DM, Davies S, Puchnarewicz M, Button J, Archer R, Ovaska H, Ramsey J, Lee T, Holt DW, Dargan PI (2010b) Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 6:327-330